drugset / Trial / NCT01057017
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Phase 2
Terminated
5 enrolled
Brown University
Rhode Island Hospital · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-04
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped: “possible lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |